YOUNG, JOEL MD PC
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1999-01-01
- Employees
- 11
- Market Cap
- -
- Website
- https://www.rcbm.net
Clinical Trials
4
Active:0
Completed:3
Trial Phases
1 Phases
Phase 4:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 4
4 (100.0%)A Trial of Dyanavel XR in Treating Co-occurring Fatigue Symptoms in Adults With Attention Deficit Hyperactivity Disorder (ADHD).
Phase 4
Recruiting
- Conditions
- Attention Deficit Hyperactivity DisorderAttention Deficit DisorderFatigue
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-02-08
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Rochester Center for Behavioral Medicine
- Target Recruit Count
- 50
- Registration Number
- NCT06248229
- Locations
- 🇺🇸
Rochester Center for Behavioral Medicine, Rochester Hills, Michigan, United States
A Trial of Solriamfetol in the Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
Phase 4
Completed
- Conditions
- Chronic Fatigue SyndromeMyalgic Encephalomyelitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-11-09
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- Rochester Center for Behavioral Medicine
- Target Recruit Count
- 44
- Registration Number
- NCT04622293
- Locations
- 🇺🇸
Rochester Center for Behavioral Medicine, Rochester Hills, Michigan, United States
Efficacy and Safety Eval of Guanfacine Hydrochloride in Combination With Psychostimulants in Adults (18-65).
Phase 4
Completed
- Conditions
- Adult Attention-Deficit Hyperactivity Disorder
- Interventions
- First Posted Date
- 2014-05-19
- Last Posted Date
- 2014-12-04
- Lead Sponsor
- Rochester Center for Behavioral Medicine
- Target Recruit Count
- 26
- Registration Number
- NCT02141113
- Locations
- 🇺🇸
Rochester Center for Behavioral Medicine, Rochester Hills, Michigan, United States
Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults With Chronic Fatigue Syndrome
Phase 4
Completed
- Conditions
- Chronic Fatigue SyndromeCognitive Impairments
- Interventions
- Drug: Placebo "30, 50 or 70 mg"
- First Posted Date
- 2010-02-18
- Last Posted Date
- 2015-04-03
- Lead Sponsor
- Rochester Center for Behavioral Medicine
- Target Recruit Count
- 26
- Registration Number
- NCT01071044
- Locations
- 🇺🇸
Rochester Center for Behavioral Medicine, Rochester Hills, Michigan, United States
News
No news found